Clinical Competition Candidate
VRAYLAR
VRAYLAR carries substance and product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 44 months away. Active clinical competition may compress the generic entry window.
LOE window
44months
to latest listed patent expiry (March 17, 2030)
Expiry attractiveness: 4/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 17
Complexity score: 3/5
Clinical competition
Score: 4/5
Active trials linked: 55
Phase 2/3 trials: 36
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: CARIPRAZINE HYDROCHLORIDE
Applicant (NDA holder): ABBVIE INC
Confidence: High